Printer Friendly

Caisson Biotech awarded new US patent for long lasting recombinant heparosan Factor VIIa conjugate (HEPtune).

M2 EQUITYBITES-August 25, 2016-Caisson Biotech awarded new US patent for long lasting recombinant heparosan Factor VIIa conjugate (HEPtune)

(C)2016 M2 COMMUNICATIONS http://www.m2.com

Caisson Biotech reported on Wednesday the receipt of the new patent, US patent 9,370,583, from the US Patent and Trademark Office for long lasting recombinant heparosan Factor VIIa conjugate (HEPtune).

The company said the naturally occurring polysaccharide, heparosan, has proven to be as effective as polyethylene glycol (PEG) in prolonging the half-life of haemophilia FVIIa, but retains significantly higher activity (48 [+ or -] 4)%, as compared to (27 [+ or -] 1)% for a corresponding PEG conjugate.

Additionally, the company said though the recombinant FVIIa is a safe and reliable option for treatment of bleeding episodes in haemophilia patients with inhibitors, a longer acting molecule desirable for routine prophylaxis. The PEG conjugation is effective in prolonging the in vivo half-life of FVIIa.

HEPtune is a new half-life extension principle based on the conjugation of a naturally occurring heparosan polysaccharide coupled to active pharmaceutical ingredients, providing enhancement of therapeutics. Heparosan can be produced chemoenzymatically, which allows for tailoring of size and incorporation of chemical handles for drug conjugation.

According to the company, the heparosan conjugation has been developed in alliance with Presidential Professor Dr. Paul DeAngelis at the University of Oklahoma Health Sciences Center.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Aug 25, 2016
Words:229
Previous Article:Inotek Pharmaceuticals concludes recruitment under first pivotal Phase 3 MATrX-1 trial of trabodenoson for the treatment of glaucoma.
Next Article:US FDA grants tentative approval to Perrigo's generic version of Suprep.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters